Phreesia (NYSE:PHR) Rating Lowered to “Hold” at Wall Street Zen

Phreesia (NYSE:PHR) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other research analysts have also issued reports on the stock. Robert W. Baird reiterated a “neutral” rating and issued a $10.00 price objective (down from $25.00) on shares of Phreesia in a report on Tuesday, March 31st. Zacks Research lowered shares of Phreesia from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Royal Bank Of Canada assumed coverage on shares of Phreesia in a research report on Friday, January 9th. They issued a “moderate buy” rating and a $26.00 price target for the company. Citigroup reaffirmed a “neutral” rating and set a $10.00 price target (down from $25.00) on shares of Phreesia in a research note on Tuesday, March 31st. Finally, BMO Capital Markets reduced their price objective on shares of Phreesia from $32.00 to $14.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 31st. Twelve investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $22.00.

Phreesia Trading Down 0.3%

Shares of PHR stock opened at $8.35 on Friday. Phreesia has a twelve month low of $7.77 and a twelve month high of $32.76. The stock’s fifty day simple moving average is $11.92 and its 200 day simple moving average is $17.25. The company has a quick ratio of 2.44, a current ratio of 1.53 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $507.10 million, a P/E ratio of 278.20 and a beta of 0.86.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.05). Phreesia had a net margin of 0.48% and a return on equity of 3.23%. The firm had revenue of $127.07 million during the quarter, compared to the consensus estimate of $126.75 million. During the same quarter in the prior year, the business posted ($0.11) earnings per share. Phreesia’s revenue for the quarter was up 15.9% compared to the same quarter last year. As a group, sell-side analysts predict that Phreesia will post -1.1 EPS for the current fiscal year.

Insiders Place Their Bets

In other Phreesia news, insider David Linetsky sold 6,038 shares of the stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $16.36, for a total transaction of $98,781.68. Following the completion of the sale, the insider owned 223,942 shares of the company’s stock, valued at approximately $3,663,691.12. This represents a 2.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Amy Beth Vanduyn sold 2,202 shares of the stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $16.36, for a total transaction of $36,024.72. Following the sale, the senior vice president directly owned 157,349 shares of the company’s stock, valued at $2,574,229.64. This represents a 1.38% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 70,358 shares of company stock valued at $1,123,569 over the last three months. Insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Phreesia

A number of hedge funds have recently bought and sold shares of the company. Granahan Investment Management LLC lifted its holdings in Phreesia by 73.8% in the fourth quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company’s stock valued at $40,601,000 after buying an additional 1,018,987 shares during the period. Prosight Management LP acquired a new stake in Phreesia during the 4th quarter worth about $16,533,000. Millennium Management LLC raised its position in shares of Phreesia by 730.7% in the 3rd quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock worth $25,028,000 after acquiring an additional 936,033 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Phreesia in the 4th quarter worth about $15,213,000. Finally, Greenhouse Funds LLLP lifted its stake in shares of Phreesia by 16.8% in the 3rd quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock valued at $91,317,000 after purchasing an additional 557,265 shares during the period. Institutional investors own 92.10% of the company’s stock.

Key Phreesia News

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Pale Fire Capital bought about $10.4 million of PHR shares, signaling institutional conviction and providing buying support. Pale fire capital buys Phreesia (PHR) shares worth $10.4 million
• Neutral Sentiment: Analysis piece argues Phreesia may have hit a near-term bottom and is positioned to regain growth, but timing and visibility remain uncertain — a constructive long-term view that doesn’t remove near-term risk. Phreesia Hits Bottom in Q1: Rebound Ahead, Timing Uncertain
• Neutral Sentiment: Several firms (Robert W. Baird, JPMorgan, Citigroup) issued neutral ratings, suggesting cautious investor expectations rather than outright sell recommendations. Phreesia (NYSE:PHR) Earns “Neutral” Rating from Robert W. Baird Phreesia (NYSE:PHR) Earns “Neutral” Rating from JPMorgan Chase & Co. Citigroup Reaffirms Neutral Rating for Phreesia (NYSE:PHR)
• Negative Sentiment: Phreesia shares plunged after reporting its first full-year profit but issuing lower-than-expected 2027 revenue guidance; the market punished the weaker outlook despite the profit. Phreesia (PHR) Is Down 25.5% After First Full-Year Profit But Lower 2027 Revenue Guidance
• Negative Sentiment: A class-action / fraud investigation filing (Schall Law Firm) was announced, raising legal and reputational risk that can weigh on the stock. PHR Investors Have Opportunity to Join Phreesia, Inc. Fraud Investigation with the Schall Law Firm
• Negative Sentiment: Multiple brokers cut expectations and targets (Needham, Canaccord lowered target to $22, Stephens and BMO issued pessimistic forecasts), increasing downward pressure via weaker sell-side guidance. Needham & Company LLC Has Lowered Expectations for Phreesia (NYSE:PHR) Stock Price Canaccord Genuity Group Lowers Phreesia (NYSE:PHR) Price Target to $22.00 Stephens Issues Pessimistic Forecast for Phreesia (NYSE:PHR) Stock Price BMO Capital Markets Issues Pessimistic Forecast for Phreesia (NYSE:PHR) Stock Price
• Negative Sentiment: Following the earnings miss, PHR hit a new 1-year low, underscoring the immediate market reaction to weaker-than-expected results and guidance. Phreesia (NYSE:PHR) Reaches New 1-Year Low After Earnings Miss

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.